Antiviral Activity and Crystal Structures of HIV-1 gp120 Antagonists.

HIV-1 / metabolism Anti-HIV Agents / pharmacology Thiazoles / pharmacology HIV Envelope Protein gp120 / metabolism CD4 Antigens / metabolism
HIV-1 antiviral crystal structure cytotoxicity envelope glycoprotein (Env) gp120 antagonist

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
15 Dec 2022
Historique:
received: 22 11 2022
revised: 10 12 2022
accepted: 14 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 27 12 2022
Statut: epublish

Résumé

As part of our effort to discover drugs that target HIV-1 entry, we report the antiviral activity and crystal structures of two novel inhibitors in a complex with a gp120 core. NBD-14204 showed similar antiviral activity against all the clinical isolates tested. The IC

Identifiants

DOI: 10.3390/ijms232415999 PMID: 36555641 PMC: PMC9784924
pubmed: 36555641
pii: ijms232415999
doi: 10.3390/ijms232415999
pmc: PMC9784924
pii:
doi:

Substances chimiques

Anti-HIV Agents 0
Thiazoles 0
HIV Envelope Protein gp120 0
CD4 Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : R01 AI104416
Pays : United States

Références

Bioorg Med Chem. 2021 Feb 15;32:116000
pubmed: 33461144
J Virol. 2006 Dec;80(23):11776-90
pubmed: 16971434
J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):299-307
pubmed: 29206721
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
J Med Chem. 2020 Feb 27;63(4):1724-1749
pubmed: 32031803
ACS Chem Biol. 2006 Dec 20;1(11):702-12
pubmed: 17184135
J Med Chem. 2015 Sep 10;58(17):6909-6927
pubmed: 26301736
J Virol. 2009 Aug;83(15):7783-8
pubmed: 19474105
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Nature. 2003 Mar 20;422(6929):307-12
pubmed: 12646921
Eur J Med Chem. 2018 Jun 25;154:367-391
pubmed: 29860061
Antimicrob Agents Chemother. 2011 Feb;55(2):729-37
pubmed: 21078948
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
J Med Chem. 2012 May 24;55(10):4764-75
pubmed: 22524483
J Virol. 1990 Nov;64(11):5270-6
pubmed: 2214018
Virology. 2009 Mar 15;385(2):505-20
pubmed: 19167740
Science. 2004 Mar 26;303(5666):2019-22
pubmed: 15044802
J Antimicrob Chemother. 2018 Jan 01;73(1):109-117
pubmed: 29029095
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
J Med Chem. 2012 May 10;55(9):4382-96
pubmed: 22497421
J Med Chem. 2003 Sep 25;46(20):4236-9
pubmed: 13678401
Bioorg Med Chem. 2015 Dec 15;23(24):7618-28
pubmed: 26602829
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5663-8
pubmed: 22451932
AIDS Res Hum Retroviruses. 2002 May 20;18(8):567-76
pubmed: 12036486
J Med Chem. 2018 Jul 26;61(14):6308-6327
pubmed: 29920093
J Med Chem. 2017 Apr 13;60(7):3124-3153
pubmed: 28266845
PLoS One. 2014 Jan 28;9(1):e85940
pubmed: 24489681
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Antimicrob Agents Chemother. 2014 Sep;58(9):5478-91
pubmed: 25001301
Viruses. 2022 Oct 16;14(10):
pubmed: 36298823
Protein Eng. 1995 Feb;8(2):127-34
pubmed: 7630882
ChemMedChem. 2018 Nov 6;13(21):2332-2348
pubmed: 30257071
J Virol. 2005 Aug;79(16):10108-25
pubmed: 16051804
J Virol. 2006 Jan;80(2):835-44
pubmed: 16378985
Bioorg Med Chem. 2016 Nov 15;24(22):5988-6003
pubmed: 27707628
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
pubmed: 18490657
J Med Chem. 2021 Nov 25;64(22):16530-16540
pubmed: 34735153
Virology. 2005 Sep 1;339(2):213-25
pubmed: 15996703

Auteurs

Francesca Curreli (F)

Laboratory of Molecular Modeling and Drug Design, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.

Young D Kwon (YD)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Isabella Nicolau (I)

Laboratory of Molecular Modeling and Drug Design, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.

Giancarla Burgos (G)

Laboratory of Molecular Modeling and Drug Design, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.

Andrea Altieri (A)

EDASA Scientific srls, Via Stingi 37, 66050 San Salvo, Italy.
ORCID: 0000-0002-9815-9866

Alexander V Kurkin (AV)

EDASA Scientific srls, Via Stingi 37, 66050 San Salvo, Italy.

Raffaello Verardi (R)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Peter D Kwong (PD)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Asim K Debnath (AK)

Laboratory of Molecular Modeling and Drug Design, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.
ORCID: 0000-0003-2761-0506

Articles similaires

Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia.

Ayantu Gudina, Moges Wordofa, Fekadu Urgessa
1.00
Humans Female Male Adult HIV Infections

Reconciling founder variant multiplicity of HIV-1 infection with the rate of CD4

James Baxter, Ch Julián Villabona-Arenas, Robin N Thompson et al.
1.00
Humans HIV-1 HIV Infections CD4-Positive T-Lymphocytes CD4 Lymphocyte Count

Transcriptomic study reveals alteration in the expression of long non-coding RNAs (lncRNAs) during reversal of HIV-1 latency in monocytic cell line.

Ankita Rai, Aradhana Singh, Ritu Gaur et al.
1.00
RNA, Long Noncoding Humans Virus Latency Monocytes HIV-1

Stochastic optimal control of pre-exposure prophylaxis for HIV infection for a jump model.

Jasmina Ɖorđević, Kristina Rognlien Dahl
1.00
Stochastic Processes Humans HIV Infections Pre-Exposure Prophylaxis Mathematical Concepts

Classifications MeSH

questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Antiviral Activity and Crystal Structures of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antirétroviraux › Agents antiVIH › Antiviral Activity and Crystal Structures of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Thiazoles › Antiviral Activity and Crystal Structures of...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antigènes du VIH › Protéine d'enveloppe gp120 du VIH › Antiviral Activity and Crystal Structures of...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Antigènes CD4 › Antiviral Activity and Crystal Structures of...